Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss.
antidepressant
diabetes
glucagon-like peptide-1 receptor agonist
obesity
weight loss
Journal
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
ISSN: 8755-1225
Titre abrégé: J Pharm Technol
Pays: United States
ID NLM: 8504643
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
2
9
2022
Statut:
ppublish
Résumé
Depression and obesity have a bidirectional relationship making the management of one, without the other, problematic. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a preferred medication class for diabetes and obesity treatment given their weight loss effect; however, it is not known how antidepressants impact this effect. To assess the impact of antidepressant use on GLP-1 RA-associated weight loss in patients with or without type 2 diabetes mellitus. This was a retrospective, propensity matched, cohort study conducted using TriNetX. The study identified patients initiating a GLP-1 RA being treated with citalopram/escitalopram, bupropion, or no antidepressant. Cohorts were propensity score matched to analyze the primary outcome of mean end-of-study (77-371 days) body weight. An initial query identified 31 273 patients eligible for analysis (30 160 receiving no antidepressant, 311 receiving bupropion, and 802 receiving citalopram/escitalopram). After propensity score matching, the study found patients receiving citalopram/escitalopram were taking more antidiabetic therapies at baseline compared with patients not treated with an antidepressant. Patients in the antidepressant cohorts experienced less weight loss compared with their respective matched cohorts not receiving antidepressants (citalopram/escitalopram -0.73 kg versus -1.74 kg; bupropion -0.84 kg versus -3.46 kg). Only the bupropion cohort was significantly heavier at end-of-study versus the non-antidepressant cohort (108 kg versus 103 kg, Antidepressants may diminish the weight loss effect of GLP-1 RAs. Additional research is needed to assess whether all GLP-1 RAs are affected similarly and the optimal weight loss strategies in patients receiving antidiabetic therapy with comorbid depression.
Sections du résumé
Background
UNASSIGNED
Depression and obesity have a bidirectional relationship making the management of one, without the other, problematic. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a preferred medication class for diabetes and obesity treatment given their weight loss effect; however, it is not known how antidepressants impact this effect.
Objective
UNASSIGNED
To assess the impact of antidepressant use on GLP-1 RA-associated weight loss in patients with or without type 2 diabetes mellitus.
Methods
UNASSIGNED
This was a retrospective, propensity matched, cohort study conducted using TriNetX. The study identified patients initiating a GLP-1 RA being treated with citalopram/escitalopram, bupropion, or no antidepressant. Cohorts were propensity score matched to analyze the primary outcome of mean end-of-study (77-371 days) body weight.
Results
UNASSIGNED
An initial query identified 31 273 patients eligible for analysis (30 160 receiving no antidepressant, 311 receiving bupropion, and 802 receiving citalopram/escitalopram). After propensity score matching, the study found patients receiving citalopram/escitalopram were taking more antidiabetic therapies at baseline compared with patients not treated with an antidepressant. Patients in the antidepressant cohorts experienced less weight loss compared with their respective matched cohorts not receiving antidepressants (citalopram/escitalopram -0.73 kg versus -1.74 kg; bupropion -0.84 kg versus -3.46 kg). Only the bupropion cohort was significantly heavier at end-of-study versus the non-antidepressant cohort (108 kg versus 103 kg,
Conclusion and Relevance
UNASSIGNED
Antidepressants may diminish the weight loss effect of GLP-1 RAs. Additional research is needed to assess whether all GLP-1 RAs are affected similarly and the optimal weight loss strategies in patients receiving antidiabetic therapy with comorbid depression.
Identifiants
pubmed: 36046348
doi: 10.1177/87551225221110850
pii: 10.1177_87551225221110850
pmc: PMC9420918
doi:
Types de publication
Journal Article
Langues
eng
Pagination
283-288Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Drugs. 2015 Jul;75(11):1269-80
pubmed: 26105116
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
Gen Hosp Psychiatry. 2015 Jan-Feb;37(1):46-8
pubmed: 25467076
N Engl J Med. 2019 Dec 19;381(25):2440-2450
pubmed: 31851800
Patient Prefer Adherence. 2020 Nov 27;14:2337-2345
pubmed: 33273810
BMJ. 2018 May 23;361:k1951
pubmed: 29793997
Drug Des Devel Ther. 2019 Aug 22;13:2985-2996
pubmed: 31686781
BMJ. 2012 Jan 10;344:d7771
pubmed: 22236411
Metabolism. 2020 Dec;113:154378
pubmed: 33002478
Int J Clin Pract. 2021 Sep;75(9):e14060
pubmed: 33527605
Drugs. 2021 Jun;81(8):881-893
pubmed: 33929717
Prim Care Companion CNS Disord. 2021 Sep 9;23(5):
pubmed: 34507389
JAMA. 2015 Aug 18;314(7):687-99
pubmed: 26284720
Circulation. 2014 Jun 24;129(25 Suppl 2):S102-38
pubmed: 24222017
Obes Sci Pract. 2017 Jul 20;3(3):342-351
pubmed: 29071110
J Affect Disord. 2021 Jan 1;278:131-135
pubmed: 32956962
EClinicalMedicine. 2021 Nov 27;42:101213
pubmed: 34877513
Pharmacy (Basel). 2018 May 14;6(2):
pubmed: 29757930
J Clin Psychiatry. 2016 Sep;77(9):e1124-e1129
pubmed: 27487004